RalphJHaukeMD

Oncology • Omaha, NE

Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative, Melanoma

Nebraska Cancer Specialists

Join to view full profile

Dr. Hauke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hauke's full profile

Already have an account?

Office
8303 Dodge St
Ste 250
Omaha, NE 68114
Phone+1 402-354-8124

Fax+1 402-354-8127
Is this information wrong?

Education & Training

University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2001
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1993 - 1996
Universidad de Panama Faculty of MedicineClass of 1990

Certifications & Licensure

NE State Medical License 1996 - 2024
IA State Medical License 1995 - 1997
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer Start of enrollment: 2004 Aug 31
Completed
Phase 1
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Aug 15
Completed
Phase 1
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Talabostat in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2006 Dec 01
Withdrawn
Phase 2
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2007 Mar 01
Terminated
Phase 2
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma Start of enrollment: 2007 Oct 02
Completed
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Start of enrollment: 2013 May 14
Completed
Phase 4
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative) Start of enrollment: 2013 Oct 01
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18
Completed
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Start of enrollment: 2018 May 07
Terminated
Phase 2
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 3
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer Start of enrollment: 2021 Feb 23
Terminated
Phase 1
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Start of enrollment: 2021 Oct 26
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer Start of enrollment: 2023 Jan 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.
Jeremie Calais, Linda Gardner, Ralph J Hauke, Ayse T Kendi, Neal D Shore, Song Zhao, Stephen M Eulau> ;Cancer Treatment Reviews. 2023 Apr 1
5 citations
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II stud...
Monika Joshi, Leonard Tuanquin, Junjia Zhu, Vonn Walter, Todd Schell, Matthew Kaag, Deepak Kilari, Jiangang Liao, Sheldon L Holder, Hamid Emamekhoo, Alexander Sankin, ...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
5 citations
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Neal Shore, Begoña Mellado, Satish Shah, Ralph Hauke, Dan Costin, Nabil Adra, Marie Cullberg, Carlos Fernandez Teruel, Thomas Morris> ;Clinical Genitourinary Cancer. 2023 Apr 1
89 citations
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
W Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, Hikmat Al-Ahmadie, Hamid Emamekhoo, Ralph J Hauke, Alexander V Louie, Matthew I Milowsky, Ana M Molina, Trac...> ;Journal of Clinical Oncology. 2022 Sep 1
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
Tomi Jun, Noah M Hahn, Guru Sonpavde, Constantine Albany, Gary R MacVicar, Ralph Hauke, Mark Fleming, Theodore Gourdin, Bagi Jana, William K Oh, Patricia Taik, Huan Wa...> ;The Oncologist. 2022 Jun 8
53 citations
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh K...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
2 citations
An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Merve Hasanov, Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels, Lawrence E. Flaherty, Sigrun Hallmeyer, Mohammed M. Milhem, Lynn ...> ;Oncoimmunology. 2021 Oct 9
59 citations
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, David Smith, Michael T. Schweizer, Mark N. Stein, Vasileios J. Assikis, Przemyslaw Twardowski, Thomas W. Flaig, Russell Z...> ;Journal of Clinical Oncology. 2021 Feb 22
11 citations
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Joseph I. Clark, Brendan Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin, Ajjai Alva, Theodore F. Logan, Ralph J. Hauke, Gerald P Miletello, Ulka N. Vaishampay...> ;Journal of Investigative Medicine. 2021 Feb 4
39 citations
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Vogelzang, N., Olsen, M., McFarlane, J., Arrowsmith, E., Bauer, T., Jain, R., Somer, B., Lam, E., Kochenderfer, M., Molina, A., Doshi, G., Lingerfelt, B., Hauke, R., G...> ;Clinical Genitourinary Cancer. 2020 Dec 1
12 citations
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina, Ralph J Hauke, James A Reeves, Sunil Babu, Peter Van Veldhuizen, Bradley Somer, Vijay ...> ;Clinical Genitourinary Cancer. 2020 Dec 1
19 citations
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.
, , , , , , , , , , , , , , , , , > ;Molecular Pharmacology. 2019 Aug 1
18 citations
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H. Voss, Rupal S. Bhatt, Nicholas J. Vogelzang, Mayer Fishman, Robert S. Alter, Brian I. Rini, J. Thaddeus Beck, Monika Joshi, Ralph J. Hauke, Michael B. Atkins...> ;Cancer. 2019 Jul 15
33 citations
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM re...
Mayer Fishman, Janice P. Dutcher, Joseph I. Clark, Ajjai Alva, Gerald P Miletello, Brendan Curti, Neeraj Agarwal, Ralph J. Hauke, Kathleen M. Mahoney, Helen Moon, J. T...> ;Journal for Immunotherapy of Cancer. 2019 Mar 27
Apalutamide for the treatment of patients with castration-resistant prostate cancer.
R Hauke> ;Drugs of Today. 2018 Oct 1
61 citations
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
Shirish M. Gadgeel, James P. Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C. Villaruz, Matthew A. Gubens, Ralph Hauke, James Chih-Hs...> ;Lung Cancer. 2018 Nov 1
89 citations
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D. Galsky, Huan Wang, Noah M. Hahn, Przemyslaw Twardowski, Sumanta K. Pal, Costantine Albany, Mark D. Fleming, Alexander Starodub, Ralph J. Hauke, Menggang Yu,...> ;European Urology. 2017 Dec 13
61 citations
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Dana E. Rathkopf, Matthew R. Smith, Charles J. Ryan, William R. Berry, N.D. Shore, Glenn Liu, Celestia S. Higano, Joshi J. Alumkal, Ralph J. Hauke, Ronald F. Tutrone, ...> ;Annals of Oncology. 2017 Sep 1
1 citations
Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.
Ralph J. Hauke, Tristan M. Sissung, William D. Figg> ;Cancer Biology & Therapy. 2017 Jul 5
62 citations
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald F. Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna...> ;Clinical Cancer Research. 2017 Jul 15
25 citations
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
67 citations
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A. Daniels, Michael K.K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald P Miletello, Th...> ;Cancer Immunology, Immunotherapy. 2016 Oct 6
162 citations
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideli...
Matthew I. Milowsky, R. Bryan Rumble, Christopher M. Booth, Timothy D. Gilligan, Libni J. Eapen, Ralph J. Hauke, Pat Boumansour, Cheryl T. Lee> ;Journal of Clinical Oncology. 2016 Sep 27
63 citations
MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling.
Imayavaramban Lakshmanan, Ralph J. Hauke, Shiv Ram Krishn, S Paknikar, Parthasarathy Seshacharyulu, Saswati Karmakar, Rama Krishna Nimmakayala, Garima Kaushik, Sonny L...> ;Oncogene. 2016 Aug 4
4 citations
Sequential Therapy in Metastatic Renal Cell Carcinoma
Bradford R Hirsch, John M. Burke, Manish Agrawal, Ralph J. Hauke, Thomas E. Hutson, Mark D. Fleming, Nicholas J. Vogelzang> ;Journal of Kidney Cancer and VHL. 2016 Apr 5
Join now to see all

Lectures

8th Annual Chicago Supportive Oncology Conference
Global Academy for Medical Education (Elsevier), Chicago, Illinois - 10/26/2012

Press Mentions

ASCO Announces 2020 AwardsApril 24th, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish

Hospital Affiliations

CHI Health Creighton University Medical Center - Bergan MercyOmaha, Nebraska
CHI Health ImmanuelOmaha, Nebraska
CHI Health Creighton University Medical CenterOmaha, Nebraska
Nebraska Methodist HospitalOmaha, Nebraska
Nebraska Medicine - Nebraska Medical CenterOmaha, Nebraska
Methodist Fremont HealthFremont, Nebraska